Refining risk stratification of patients with early breast cancer eligible for adjuvant abemaciclib or ribociclib
Luca Arecco, Eva Blondeaux, Marco Bruzzone, Evandro de Azambuja et autres
0 citationsJNCI Journal of the National Cancer Institute
Lucia Del Mastro
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
730Publications signalées
21822Citations signalées
5Affiliations récentes
Institutions déclarées
Domaines associés
Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesCancer Treatment and PharmacologyHER2/EGFR in Cancer ResearchEstrogen and related hormone effects
Publications récentes
CDK4/6i in the Underrepresented Histological Subtypes of HR±/HER2- Metastatic Breast Cancer: A Real-World Cohort Study of Effectiveness and Safety
Claudia von Arx, Alessandra Calabrese, Michela Piezzo, Vincenzo Di Lauro et autres
0 citationsClinical Breast Cancer
Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer
Maria Vittoria Dieci, Elisa Gasparini, Lorenzo Nicolè, Peter Schmid et autres
0 citationsClinical Cancer Research
Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis
Roberta Caputo, Giuseppe Buono, C. Martinelli, A. Botticelli et autres
0 citationsESMO Open
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial
Chiara Molinelli, Virginia Delucchi, Eva Blondeaux, Luca Boni et autres
0 citationsThe Breast
Supplementary Methods S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
Supplementary Figure S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
Supplementary Figure S3 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
Supplementary Figure S2 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
Supplementary Data S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
Supplementary Table S3 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
Supplementary Table S2 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, Alberto Zambelli et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.